Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours

NCT02941523 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: NOX66
DRUG: Carboplatin

Sponsor

Noxopharm Limited